Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21987549 | 0.85 | TP53 (0.39) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL20261186 | 0.85 | TP53 (0.39) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| Acetic Acid SCHEMBL9900974 | 0.85 | ACE (0.46) | JAK2JAK1TYK2JAK3ACE | |
| Acetic Acid SCHEMBL9900145 | 0.83 | ACE (0.45) | JAK2JAK1TYK2JAK3ACE | |
| Acetic Acid SCHEMBL9900147 | 0.81 | ACE (0.37) | JAK2JAK1TYK2JAK3ACE | |
| Acetonitrile SCHEMBL5397687 | 0.79 | ACE (0.36) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL5641934 | 0.78 | EPHX1 (0.43) | ACE | |
| Ammonia Solution, Strong SCHEMBL7435862 | 0.78 | ACE (0.39) | JAK2JAK1TYK2JAK3ACE | |
| SCHEMBL21987659 | 0.78 | PLG (0.50) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL6274517 | 0.75 | ALOX15 (0.42) | JAK2JAK1TYK2JAK3ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178680-B2 | Process for the preparation of Montelukast and its pharmaceutically acceptable salts | MSN LABORATORIES LIMITED (IN) | 2012-05-15 | — | — | US | disclosed |
| EP-2231613-B1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LTD (IN) | 2011-10-12 | — | — | EP | disclosed |
| US-20100292251-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| EP-2231613-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | Torrent Pharmaceuticals Ltd. (IN) | 2010-09-29 | — | — | EP | disclosed |
| US-20100063291-A1 | PROCESS FOR PREPARATION OF SOLID MONTELUKAST | DR. REDDY'S LABORATORIES, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2009113087-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-09-17 | — | — | WO | disclosed |
| US-20090171092-A1 | Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts | MSN LABORATORIES LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| US-7189853-B2 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-03-13 | — | — | US | disclosed |
| US-20050234241-A1 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (montelukast) and its pharmaceutically acceptable salts | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2005-10-20 | — | — | US | disclosed |
| EP-0500360-B1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-06-25 | — | — | EP | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171092-A1 | Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts | CMA1, TPSD1, AP1S1 | ALDH1A1 383/4885JAK2 2110/4885JAK1 729/4885 |
| US-20100292251-A1 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF | CMA1, CYSLTR2, CYSLTR1 | ALDH1A1 77/4885JAK2 347/4885JAK1 164/4885 |
| US-20050234241-A1 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (montelukast) and its pharmaceutically acceptable salts | CMA1, HRH2, HRH1 | ALDH1A1 553/4885JAK2 3034/4885JAK1 1270/4885 |
| US-20100063291-A1 | PROCESS FOR PREPARATION OF SOLID MONTELUKAST | MPST, CMA1, TPMT | ALDH1A1 3561/4885JAK2 277/4885JAK1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.